Clinical trial · Interventional
Respiratory Viral Infections During Acute Myeloid Leukemia (AML)Chemotherapy Related Aplasia
Incidence of Respiratory Viral Infections During AML Induction and Consolidation Chemotherapy
NCT01819792CI-TRIAL-00032628LAMVIREcompletedPhase 4ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Infectious morbidity and mortality is a major complication of AML (Acute Myeloid Leukemia) induction and consolidation chemotherapies related aplasia. The main aim of this study is to measure incidence of respiratory viral infections during AML induction and consolidation chemotherapy related aplasia. Primary end point is a positive polymerase chain reaction(PCR)associated with clinical signs.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Acute Myeloid Leukemia | Acute Myeloid Leukemia | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Multiplex respiratory viral PCR | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- OTHER
- label
- patient with Acute Myeloïd Leukemia
- interventionNames
- Other: Multiplex respiratory viral PCR
Primary outcomes (1)
- measure
- positivity of the viral PCR in the presence of clinical signs during periods of positivity of the PCR in the presence of clinical signs
- timeFrame
- at day 15
- description
- Positivity of the viral PCR in the presence of clinical signs during periods of Aplasia following chemotherapy induction and consolidation defining viral infection.
Secondary outcomes (5)
- measure
- seasonal viral infection incidence measure
- timeFrame
- 18 months after inclusion
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 85 Years
Show eligibility criteria text
Inclusion Criteria: * Patients over 18 years old with an AML diagnostic and treated with induction and consolidation chemotherapy. Patients enrolled in another protocol may be included. * Patients with relapsed leukemia who are treated with a salvage intensive therapy stay in the study * Patients who have signed a consent policyholder Exclusion Criteria: * patients under 18 years old * patients treated with another treatment than induction and consolidation chemotherapy * pregnant women * patients HIV, HBV or HBC positive * patients with a positive PCR at J1 * patients treated with an antiviral treatment or an immunosuppressive treatment for another pathology * patients under guardianship * Primitive immunity Deficit
References
Publications (0)
Data not yet available
No reference posted for this study.